Turosteride, with the CAS number 137099-09-3, is a synthetic compound that belongs to the class of steroidal 5α-reductase inhibitors. It is primarily investigated for its potential therapeutic applications in conditions related to androgen excess, such as benign prostatic hyperplasia and androgenetic alopecia. The compound functions by inhibiting the enzyme 5α-reductase, which converts testosterone into dihydrotestosterone (DHT), a more potent androgen associated with various androgen-dependent conditions. Turosteride is characterized by its specific structural modifications that enhance its selectivity and potency compared to other inhibitors in its class. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. Research into Turosteride continues to explore its potential benefits and side effects, contributing to the understanding of androgen modulation in therapeutic contexts. As with any pharmaceutical agent, comprehensive studies are essential to establish its clinical utility and regulatory approval.

Turosteride

137099-09-3: 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-1,4a,6a-trimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-, 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-1,4a,6a-trimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2-oxo-, [4aR-(4aα,4bβ,6aα,7α,9aβ,9bα,11aβ)]-, Turosteride, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-Hexadecahydro-1,4a,6a-trimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxamide, 4-Azaandrostane-17-carboxamide, 4-methyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-3-oxo-, (5α,17β)-

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and

CAS 137099-09-3: Turosteride

Turosteride

Ref: TM-T71703

Turosteride

Ref: 54-BUP03047